
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
For Sponsorship questions: Jules LeoJules.Leo@ubm.com 201-984-6267Cindy FlaumCindy.Flaum@ubm.com 201-984-6266Help with registration:showsupport@ubm.com
For Sponsorship questions: Jules Leo
201-984-6267
Cindy FlaumCindy.Flaum@ubm.com
201-984-6266
Help with registration:showsupport@ubm.com




